DM² celebrate with mid-point IDT demonstrator

This summer, CMAC’s Digital Medicines Manufacturing (DM²) research centre, co-funded through the Made Smarter Challenge at UKRI, has reached the mid-point in it’s funding timeline. To celebrate this milestone, the team came together at CMAC’s main offices in the Technology and Innovation Centre at the University of Strathclyde, Glasgow, UK.

The work undertaken by the DM² team is split over five ‘Platforms’ with each presenting key outputs to date. By bringing these together as input into the overarching, integrated DM² demonstrator, the team highlights the benefit of working together across multiple disciplines. DM² is an exemplar of expertise in data, autonomous systems, quality control mechanisms, supply chains and engagement coming together to create a cohesive approach to developing innovative industrial digital technologies to drive the digitalisation of medicines manufacturing.

The demonstrator will now be further developed for an external showcase as part of the upcoming CMAC Open Days. Register today on the CMAC Open Days website.

DM² team members getting a demonstration of the autonomous microscale manufacturing set-up being developed by DM² Platform 2.

DM² team members getting to immersed in Augmented Reality skills development tools being developed by DM² Platform 5

DM² Platform 3 team members sharing their digital quality control tools with the rest of the DM² team.

DM² Platform 2 team members sharing their automated medcine manufacturing systems with the rest of the DM² team.

DM² Platform 1 team members sharing the databases and interactive interfaces they are developing with the rest of the DM² team.

DM² Platform 4 team members sharing their pharmaceutical supply chain case studies with the rest of the DM² team.

DM² is an ambitious 3.5 year programme, co-created and co-delivered with industry. The goal is to develop Industrial Digital Technologies that are successfully adopted into industry, increasing adaptability and productivity while enabling a reduction in costs, medicines shortages and waste.

With the focus on enabling digital design, DM² is a flagship programme for delivering the centre for Continuous Manufacturing and Advanced Crystallisation’s (CMAC) strategic priorities to improve digital maturity in medicines manufacturing and develop the workforce of the future who can flourish in these digitalised lab environments.